ClinicalTrials.gg
Status unknownNCT04651036Updated Dec 3, 2020

A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects

A Phase 1 interventional study of QL0605 and US Neulasta in Healthy, sponsored by Qilu Pharmaceutical Co., Ltd.. Status unknown at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-03.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Other

The sponsor has not verified this record recently (last verified Nov 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The study was an assessor-blind, balanced, parallel, randomized, two-treatment, comparative immunogenicity study of multiple doses of subcutaneous (SC) Pegfilgrastim injection (6 mg/0.6 mL; Qilu Pharmaceutical Co., Ltd. proposed biosimilar QL0605 compared to innovator product, US-Neulasta) in healthy, adult, human subjects.

Read the detailed description

This is a multi-center, randomized, double-blind, single-dose, 2-period parallel-arm study designed to assess the immunogenicity of QL0605 and US-Neulasta.

A total of 300 healthy male and female subjects aged 18-55 years (inclusive) will be included and randomized to receive either 2 s.c. doses of QL0605 or US-NeulastaP®P in a ratio of 1:1. After the Screening Period of up to 4 weeks the subject will be randomly allocated to one of the 2 parallel treatment arms. All subjects will receive 1 s.c. injection of 6 mg QL0605 or 6 mg NeulastaP®P (US) in Treatment Period 1 and 1 s.c. injection of 6 mg QL0605 or 6 mg NeulastaP®P in Treatment Period 2. The interval between doses is ≥ 42 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must give written before any assessment is performed;
  2. Subjects must be a healthy male or female aged 18 to 55 years (both inclusive) at the time of informed consent;
  3. Body weight ≥60 kg (males) or ≥50 kg (females) at the Screening Visit;
  4. The (BMI) between 18.5 to 29.9 kg/m2 (inclusive) at the Screening Visit (BMI = Body weight (kg)/[Height (m)]2);
  5. and total leukocyte count are within the normal laboratory reference ranges; count, hematocrit, and results are not below the lower limit of laboratory reference ranges; reticulocyte count is not above the upper limit of laboratory reference ranges; all other laboratory parameters within reference ranges or showing no deviations as judged by the Investigator. If the results of the laboratory parameters (other than total leukocyte count, platelet count, neutrophil count, hematocrit, reticulocyte count and hemoglobin) are outside the normal reference ranges, the subject may be included only if the Investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate for the population under study;
  6. Female subjects must either be:

    • of non-:

      • (defined as at least 1 year without any menses) prior to the Screening Visit, and the follicle stimulating hormone levels indicative of menopause according to local laboratory reference ranges at Screening, or
      • Documented permanent surgically sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy) since at least 6 weeks before the Screening Visit
    • or, if of childbearing potential:

      • Agree not to try to become pregnant during the clinical study and for 49 days after the last IMP administration and
      • Must have a negative serum pregnancy test at screening and
      • If heterosexually active, agree to consistently use 2 forms of (1 of which is a highly effective method† and 1 must be a barrier method‡) from screening and throughout the study period, and for 49 days after last IMP administration. The highly effective method of contraception should be stable for at least 28 days prior to first IMP administration.

        • Highly effective forms of birth control include (i.e., less than 1% failure rate per year when used consistently and correctly):
    • Consistent and correct usage of established oral contraception (this is considered highly effective, because it is used in combination with a barrier method)
    • Injected or implanted hormonal methods of contraception
    • Established (with a failure rate \< 1%) intrauterine device (IUD) or intrauterine system (IUS)
    • Bilateral tubal ligation
    • Any male partner that has undergone effective surgical sterilization, provided that the partner is the sole sexual partner of the female study participant
    • Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments and complies with the preferred and usual lifestyle of the subject.

      ‡ Barrier methods of birth control include for males and females:

    • Condom without spermicidal foam/gel/film/cream/suppository or fat- or oil containing lubricant.
    • Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
  7. Female subjects must agree not to breastfeed starting at the Screening Visit and throughout the clinical study period, and for 49 days after last IMP administration;
  8. Female subjects must not donate ova starting at the Screening Visit and throughout the clinical study period, until the final Follow-up Visit;
  9. Male subjects and their female spouse/partners who are of childbearing potential must be using 2 forms of birth control (1 of which is a highly effective method† and 1 must be a barrier method‡) starting at the Screening Visit and throughout the study period and for 49 days after the last IMP administration. A condom is required to be used also by vasectomized men to prevent delivery of the drug via seminal fluid;
  10. Subjects must be non-smoker, or light smokers who smoke not more than 5 cigarettes or 1 cigar or 1 pipe per day and who agree to abstain from smoking while resident at the clinical unit.

Exclusion criteria

Exclusion Criteria:

  1. Known previous exposure to filgrastim, pegfilgrastim, granulocyte colony stimulating factor (G-CSF) or any analogue of these;
  2. Positive test results for anti-PEG-GCSF-antibodies at the Screening Visit or based on historical data (not older than 3 months);
  3. Known to the study drug or any of its constituents (e.g., fructose intolerance), hypersensitivity to Escherichia coli derived proteins;
  4. History of an acute severe allergic reaction (e.g., anaphylaxis; delayed hypersensitivity reaction); concurrent or history of moderate to severe allergy requiring medical treatment (including moderate seasonal allergies); concurrent or history of latex allergy;
  5. Current evidence of atopic eczema or allergic bronchial asthma;
  6. History or current evidence of any clinically significant condition that might interfere with the distribution, metabolism or excretion of the any of the drugs;
  7. Concurrent or history of cardiac, hepatic, renal, gastrointestinal, respiratory, neurological, central nervous, mental disorders and/or hematological function disorders, which, in the judgment of the Investigator or any of the Sub-Investigators, may affect participation in this clinical study;
  8. Clinically significant vital sign abnormalities or systolic blood pressure [BP] \< 90 or > 139 mmHg, diastolic BP \< 50 or > 89 mmHg, and/or pulse \< 50 or > 90 beats per minute [bpm] at the Screening Visit (mean of triplicate measurements);
  9. Subjects with abnormal 12-lead (ECGs) ( >450 ms in males and 470 ms in females, signs of ischemia, sinus tachycardia [heart rate, HR >90] or sinus bradycardia [HR \<50], ventricular conduct delay [QRS >120 ms] or others) which, in the judgment of the Investigator or any of the Sub-investigators, may be clinically relevant;
  10. Renal impairment with estimated (eGFR) \< 90 mL/min/1.73 m2, based on calculation by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
  11. Any clinically relevant laboratory findings that, in the opinion of the Investigator, would preclude inclusion in the trial; including (ALT), aspartate aminotransferase (AST), and (total) > (ULN). If any of these tests are out-of-range, the tests can be repeated once;
  12. Previous or concurrent ;
  13. First degree relatives with hematological malignancy;
  14. Clinically significant active infection within 4 weeks before IMP administration;
  15. Any past or concurrent medical conditions that potentially increase the subject's risks or affect the evaluation of any study results, like medical history with evidence of clinically relevant pathology e.g., sickle cell disorders, spleen pathologies, hematologic malignancies or myelodysplastic disorders, and pulmonary illnesses such as Acute Respiratory Distress Syndrome, interstitial pneumonia, pulmonary edema, pulmonary infiltrates and pulmonary fibrosis;
  16. Subject exhibiting spleen enlargement (as determined by ultrasound assessment) or other relevant abnormality which is, at the discretion of the Investigator, a for treatment with pegfilgrastim;
  17. Presence of any clinically significant finding that, in the opinion of the Investigator, would preclude continuation in the study;
  18. Participation (last dosing) in a previous clinical trial with an experimental drug within 3 months before the first administration of the IMP or five half lives of the drug, whichever is longer, prior to dosing;
  19. Use of depot injectable solutions within 6 months before IMP administration. Hormonal depot injections for or hormonal replacement therapy are allowed;
  20. Intake of drugs and/or drugs with a long half-life within 4 weeks before IMP administration;
  21. Positive test results for surface antigen (HbsAg), anti hepatitis B core (anti-HBc) antibodies indicative of active hepatitis, hepatitis A virus antibodies (immunoglobulin M [IgM]), virus (HCV) antibodies or (HIV) type-1 and/or type-2 antibodies at the Screening Visit;
  22. Has a history of chronic drug or alcohol abuse in the last 5 years before the date of administration of the IMP and/or positive urine drugs of abuse tests (phencyclidines, benzodiazepines, cocaine, amphetamines/ methamphetamines, cannabinoids, opiates, barbiturates, and tricyclic antidepressant drugs) and / or positive alcohol urine test at screening and admission;
  23. Subjects who regularly consume large quantities of alcohol.

    • For Berlin unit: drinking > 168 g (males) and > 84 g (females) pure alcohol per week (10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 125 mL of wine [10%]) within 3 months prior to admission to the clinical unit;
    • For London unit: drinking > 21 units (males) and > 14 units (females) of alcohol per week (beer 5%, 259 ml = 10.36 g , wine 10% 100 ml = 8 g and Spirits 40% 35 ml = 11.20 g);
  24. Not willing to abstain from xanthine-containing products from 24 hours prior to the Screening Visit and prior to the admission visit [Day -1] and during the in-house stay, and at all other times, to limit the consumption of caffeinated beverages or xanthine-containing products to no more than 6 units per day (1 unit = 120 mg of caffeine);
  25. Plasma donation within 1 month before the Screening Visit or any blood donation / blood loss > 500 mL during the 3 months before the Screening Visit, or any planned blood donation during the time the subject is on study;
  26. Use of any prescription drug (excluding hormonal contraceptives, hormone replacement therapy, and topical medications used for local treatment) or any over-the-counter drug (except ibuprofen and paracetamol) within the 2 weeks (or less than 5 x the half-life of that medication, whichever is longer) before the Baseline Visit in Period 1, which, in the judgment of the Investigator or Sub-Investigators, may affect participation in this clinical study; vitamins, minerals and nutritional supplements may be taken at the discretion of the Investigator;
  27. Subjects being on a special diet or with significant weight loss from a weight reduction diet (e.g. more than approx. 5 kg within 1 month) before the Screening Visit or unwilling to maintain the same weight for the duration of the study;
  28. Not willing to avoid poppy seeds and foods containing them for 72 hours prior to Screening and Day -1 visits;
  29. A current (suspected or confirmed) pregnancy or currently nursing (women only);
  30. Vulnerable subjects (i.e., persons under any administrative or legal supervision or persons kept in detention);
  31. Subjects who are employees of Sponsor, clinical research organization (CRO) or who is the Investigator or any sub-Investigator, research assistant, pharmacist, study coordinator, other site staff or relative thereof directly involved in the conduct of the clinical study;
  32. Subjects who are not able to read, speak and understand the German language (Berlin unit) or the English language (London unit);
  33. Any psychological or emotional problems/disorders or resultant therapy that is likely to invalidate , or limit the ability of the subject to comply with the protocol requirements.
  34. Subject has a positive PCR test result for SARS-CoV-2 before randomization.
  35. Subject has clinical signs and symptoms consistent with COVID-19, e.g., fever, dry cough, dyspnea, sore throat, fatigue or confirmed current infection by appropriate laboratory test within the last 4 weeks prior to or at screening or on admission.
  36. Subject who had severe course of COVID-19 (extracorporeal membrane oxygenation [ECMO], mechanically ventilated).
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Pegfilgrastim biosimilar product

    QL0605 subcutaneously at a dose of 6 mg/0.6 mL.

    Drug: QL0605

  • Active comparator
    US Neulasta

    US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.

    Drug: US Neulasta

Interventions

  • DrugQL0605

    a pegfilgrastim biosimilar to US Neulasta.

    Also known as: pegfilgrastim

  • US Neulasta

    Also known as: pegfilgrastim

06

What researchers measure

Primary outcomes

  1. Incidence (absolute and percentage) of ADA by treatment

    Incidence (absolute and percentage) of anti-drug antibody by treatment

    Time frame: 91 days

Secondary outcomes

  1. AUC0-t

    Area under the concentration-time curve (AUC) from time zero to last quantifiable concentration

    Time frame: 91 days

  2. AUCinf

    Area under the concentration-time curve (AUC) from time zero to infinity

    Time frame: 91 days

  3. Cmax

    Maximum serum concentration

    Time frame: 91 days

  4. tmax

    time corresponding to the occurrence of Cmax

    Time frame: 91 days

  5. AUEC(0-Day41)

    Area under the ANC-time curve (AUC) from time zero to day41

    Time frame: 41 days

  6. ANC Emax

    Maximum ANC concentration

    Time frame: 91 days

07

Study locations

1 of 2 sites recruiting
  • Parexel International GmbH Early Phase Clinical Unit Berlin
    Berlin, Germany
    Not yet recruiting
    • Thomas Koernicke · Contact
    • Thomas Koernicke · Principal investigator
  • Parexel Early Phase Clinical Unit
    London, United Kingdom
    Recruiting
    • Jana Wolfova · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2020 (actual). Primary completion is estimated for Nov 2021, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2020
First posted
Dec 3, 2020
StartActual
Nov 6, 2020
Primary completionEst.
Nov 30, 2021
CompletionEst.
Nov 30, 2022
Last update
Dec 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04651036
Responsible party
Sponsor
First posted
Dec 3, 2020
Start date
Nov 6, 2020
Primary completion
Nov 30, 2021 (estimated)
Completion
Nov 30, 2022 (estimated)
Last update
Dec 3, 2020

Study contacts

Thomas Koernicke, MD
Contact
Thomas.Koernicke@parexel.com
+49 (0)30 30685 9676
Jana Wolfova, MD
Contact
Jana.Wolfova@parexel.com
+44 (0)1895 614249
Thomas Koernicke, MD
principal investigator · Parexel International GmbH Early Phase Clinical Unit Berlin

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegfilgrastim

Start the discussion